Literature DB >> 15815207

Unemployment and disability in patients with moderately to severely active Crohn's disease.

Brian G Feagan1, Mohan Bala, Songkai Yan, Allan Olson, Stephen Hanauer.   

Abstract

GOALS: Unemployment and disability rates in Crohn's disease patients from the ACCENT I trial were assessed. Factors associated with employment and disability status were explored.
BACKGROUND: Limited data regarding unemployment and disability status in patients with active Crohn's disease are available. STUDY: Baseline data were used to assess unemployment and disability rates. Logistic regression analysis examined factors that were associated with employment and disability status. Analysis of variance was used to compare quality of life.
RESULTS: The baseline full-and part-time employment rates were 48% and 13%, respectively, with 39% of patients unemployed and 25% receiving disability compensation. Only 14% of 225 unemployed patients felt well enough to work if a job were available. Younger age, female gender, shorter disease duration, and prior bowel resection predicted a higher likelihood of unemployment. Younger age and female gender also predicted a higher likelihood of not being employed full-time. Prior bowel resection predicted a higher likelihood of receiving disability compensation. Quality of life (Inflammatory Bowel Disease Questionnaire, Short Form-36) scores were significantly higher in employed patients.
CONCLUSIONS: Patients with moderately to severely active Crohn's disease had low employment and high disability rates. Given their economic importance, assessment of these outcomes should be integrated into future evaluations of therapy, including clinical trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15815207     DOI: 10.1097/01.mcg.0000159220.70290.41

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  30 in total

1.  The impact of the patient-centered medical home on the biologics industry, employers, and third-party payers.

Authors:  John Greenwood; David B Nash
Journal:  Biotechnol Healthc       Date:  2009

Review 2.  Systematic review: The role of race and socioeconomic factors on IBD healthcare delivery and effectiveness.

Authors:  Justin L Sewell; Fernando S Velayos
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

3.  Tailoring the treatment to the individual in Crohn's disease.

Authors:  Edouard Louis; Jacques Belaiche; Catherine Reenaers
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

4.  IBD-related work disability in the community: Prevalence, severity and predictive factors. A cross-sectional study.

Authors:  Alexis Ramos; Xavier Calvet; Beatriz Sicilia; Mercedes Vergara; Ariadna Figuerola; Jaume Motos; Adoración Sastre; Albert Villoria; Fernando Gomollón
Journal:  United European Gastroenterol J       Date:  2015-08       Impact factor: 4.623

Review 5.  Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.

Authors:  Antonio Di Sabatino; Lucio Liberato; Monia Marchetti; Paolo Biancheri; Gino R Corazza
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

6.  Optimizing management of Crohn's disease within a project management framework: results of a pilot study.

Authors:  Laurie Keefer; Bethany Doerfler; Caroline Artz
Journal:  Inflamm Bowel Dis       Date:  2011-02-23       Impact factor: 5.325

Review 7.  The pharmacoeconomics of biologic therapy for IBD.

Authors:  Russell D Cohen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

8.  Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.

Authors:  Remo Panaccione; Edward V Loftus; David Binion; Kevin McHugh; Shamsul Alam; Naijun Chen; Benoît Guerette; Parvez Mulani; Jingdong Chao
Journal:  Can J Gastroenterol       Date:  2011-08       Impact factor: 3.522

9.  Illness Perceptions and Outcomes in Patients with Inflammatory Bowel Disease: Is Coping a Mediator?

Authors:  S J H van Erp; L K M P Brakenhoff; M Vollmann; D van der Heijde; R A Veenendaal; H H Fidder; D W Hommes; A A Kaptein; Andrea E van der Meulen-de Jong; M Scharloo
Journal:  Int J Behav Med       Date:  2017-04

10.  Facilitating empowerment in employees with chronic disease: qualitative analysis of the process of change.

Authors:  Inge Varekamp; Annelies Heutink; Selma Landman; Cees E M Koning; Gabe de Vries; Frank J H van Dijk
Journal:  J Occup Rehabil       Date:  2009-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.